To verify the therapeutic potential of rAAV-CD39, the main asthmatic cardinal features, such as airway hyperresponsiveness (AHR) and eosinophilic infiltration, were analyzed after the last OVA challenge. The gene discussed is ENTPD1; the disease is airway hyperresponsiveness.